Immunitybio Inc

ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing next-generation immunotherapies that activate the patient's immune system to provide durable protection against cancer and infectious diseases. Its platforms include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies, and have generated first-in-human therapeutic agents planned for clinical trials in liquid and solid tumors. Its lead product candidate is Anktiva, an FDA-approved immunotherapy used with bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company also has 3M-052, a synthetic TLR7/8 agonist, and related formulations and technology. It has collaboration agreements with the National Cancer Institute, Serum Institute of India Private Limited, and BeOne Medicines Ltd., and license agreements with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio is based in San Diego, California.